UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 5, 2008
MEDTOX SCIENTIFIC, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
| 1-11394 |
| 95-3863205 |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
|
|
|
402 West County Road D, St. Paul, Minnesota |
| 55112 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (651) 636-7466
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
1
Item 7.01. | Regulation FD Disclosure |
On March 5, 2008, MEDTOX Scientific, Inc. (the “Company”) filed a 510(k) application with the FDA for prescription use of its MEDTOXScan® instrumented reader that is used with its drugs-of-abuse diagnostic devices. All documentation required for a traditional 510(k) submission for the MEDTOXScan® reader was filed electronically using the FDA’s most recent e-submission software. We anticipate a quicker response from the FDA by filing the e-submission for the prescription use of the reader first and then filing for OTC use. This will enable the reader to be back in the hospital market in a more timely fashion.
The information in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MEDTOX Scientific, Inc. |
Date: March 11, 2008 | By: | /s/ Richard J. Braun |
| Name: Richard J. Braun |
| Title: | Chief Executive Officer |
3